Search

Your search keyword '"Eun, Young‐Gyu"' showing total 511 results
Start Over Author "Eun, Young‐Gyu"
511 results on '"Eun, Young‐Gyu"'

8. Clinically conserved genomic subtypes of gastric adenocarcinoma

Author

Jeong, Yun Seong, Eun, Young-Gyu, Lee, Sung Hwan, Kang, Sang-Hee, Yim, Sun Young, Kim, Eui Hyun, Noh, Joo Kyung, Sohn, Bo Hwa, Woo, Seon Rang, Kong, Moonkyoo, Nam, Deok Hwa, Jang, Hee-Jin, Lee, Hyun-Sung, Song, Shumei, Oh, Sang Cheul, Lee, Jeeyun, Ajani, Jaffer A., and Lee, Ju-Seog

Published
2023
Full Text
View/download PDF

11. Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer

Author

Yim, Sun Young, Shim, Jae-Jun, Shin, Ji-Hyun, Jeong, Yun Seong, Kang, Sang-Hee, Kim, Sang-Bae, Eun, Young Gyu, Lee, Dong Jin, Conner, Elizabeth A, Factor, Valentina M, Moore, David D, Johnson, Randy L, Thorgeirsson, Snorri S, and Lee, Ju-Seog

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Liver Disease, Genetics, Liver Cancer, Orphan Drug, Biotechnology, Rare Diseases, Human Genome, Cancer, Digestive Diseases, Aetiology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Good Health and Well Being, Animals, Carcinoma, Hepatocellular, Disease Models, Animal, Genomics, Humans, Liver Neoplasms, Liver Neoplasms, Experimental, Mice, Prognosis, Developmental Biology, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Hepatocellular carcinoma (HCC) is a heterogeneous disease. Mouse models are commonly used as preclinical models to study hepatocarcinogenesis, but how well these models recapitulate molecular subtypes of human HCC is unclear. Here, integration of genomic signatures from molecularly and clinically defined human HCC (n = 11) and mouse models of HCC (n = 9) identified the mouse models that best resembled subtypes of human HCC and determined the clinical relevance of each model. Mst1/2 knockout (KO), Sav1 KO, and SV40 T antigen mouse models effectively recapitulated subtypes of human HCC with a poor prognosis, whereas the Myc transgenic model best resembled human HCCs with a more favorable prognosis. The Myc model was also associated with activation of β-catenin. E2f1, E2f1/Myc, E2f1/Tgfa, and diethylnitrosamine (DEN)-induced models were heterogeneous and were unequally split into poor and favorable prognoses. Mst1/2 KO and Sav1 KO models best resemble human HCC with hepatic stem cell characteristics. Applying a genomic predictor for immunotherapy, the six-gene IFNγ score, the Mst1/2 KO, Sav1 KO, SV40, and DEN models were predicted to be the least responsive to immunotherapy. Further analysis showed that elevated expression of immune-inhibitory genes (Cd276 and Nectin2/Pvrl2) in Mst1/2 KO, Sav1 KO, and SV40 models and decreased expression of immune stimulatory gene (Cd86) in the DEN model might be accountable for the lack of predictive response to immunotherapy.Implication: The current genomic approach identified the most relevant mouse models to human liver cancer and suggests immunotherapeutic potential for the treatment of specific subtypes. Mol Cancer Res; 16(11); 1713-23. ©2018 AACR.

Published
2018

19. Impact of subspecialty training on management of laryngopharyngeal reflux: results of a worldwide survey

Author

Lechien, Jerome R., Carroll, Thomas L., Allen, Jacqueline E., Ayad, Tareck, Enver, Necati, Eun, Young-Gyu, Perazzo, Paulo S., Ceccon, Fabio Pupo, Sant’Anna, Geraldo D., Imamura, Rui, Raghunandhan, Sampath Kumar, Chiesa-Estomba, Carlos M., Calvo-Henriquez, Christian, Saussez, Sven, Karkos, Petros D., Remacle, Marc, Akst, Lee M., and Bock, Jonathan M.

Published
2021
Full Text
View/download PDF

31. The Dubai Definition and Diagnostic Criteria of Laryngopharyngeal Reflux: The IFOS Consensus.

Author

Lechien, Jerome R., Vaezi, Michael F., Chan, Walter W., Allen, Jacqueline E., Karkos, Petros D., Saussez, Sven, Altman, Kenneth W., Amin, Milan R., Ayad, Tareck, Barillari, Maria R., Belafsky, Peter C., Blumin, Joel H., Johnston, Nikki, Bobin, Francois, Broadhurst, Matthew, Ceccon, Fabio P., Calvo‐Henriquez, Christian, Eun, Young‐Gyu, Chiesa‐Estomba, Carlos M., and Crevier‐Buchman, Lise

Abstract

Objective: The objective of this work was to gather an international consensus group to propose a global definition and diagnostic approach of laryngopharyngeal reflux (LPR) to guide primary care and specialist physicians in the management of LPR. Methods: Forty‐eight international experts (otolaryngologists, gastroenterologists, surgeons, and physiologists) were included in a modified Delphi process to revise 48 statements about definition, clinical presentation, and diagnostic approaches to LPR. Three voting rounds determined a consensus statement to be acceptable when 80% of experts agreed with a rating of at least 8/10. Votes were anonymous and the analyses of voting rounds were performed by an independent statistician. Results: After the third round, 79.2% of statements (N = 38/48) were approved. LPR was defined as a disease of the upper aerodigestive tract resulting from the direct and/or indirect effects of gastroduodenal content reflux, inducing morphological and/or neurological changes in the upper aerodigestive tract. LPR is associated with recognized non‐specific laryngeal and extra‐laryngeal symptoms and signs that can be evaluated with validated patient‐reported outcome questionnaires and clinical instruments. The hypopharyngeal–esophageal multichannel intraluminal impedance–pH testing can suggest the diagnosis of LPR when there is >1 acid, weakly acid or nonacid hypopharyngeal reflux event in 24 h. Conclusion: A global consensus definition for LPR is presented to improve detection and diagnosis of the disease for otolaryngologists, pulmonologists, gastroenterologists, surgeons, and primary care practitioners. The approved statements are offered to improve collaborative research by adopting common and validated diagnostic approaches to LPR. Level of Evidence: 5 Laryngoscope, 134:1614–1624, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Data from Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer

Author

Yim, Sun Young, primary, Shim, Jae-Jun, primary, Shin, Ji-Hyun, primary, Jeong, Yun Seong, primary, Kang, Sang-Hee, primary, Kim, Sang-Bae, primary, Eun, Young Gyu, primary, Lee, Dong Jin, primary, Conner, Elizabeth A., primary, Factor, Valentina M., primary, Moore, David D., primary, Johnson, Randy L., primary, Thorgeirsson, Snorri S., primary, and Lee, Ju-Seog, primary

Published
2023
Full Text
View/download PDF

42. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

43. Supplemental Data from Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer

Author

Yim, Sun Young, primary, Shim, Jae-Jun, primary, Shin, Ji-Hyun, primary, Jeong, Yun Seong, primary, Kang, Sang-Hee, primary, Kim, Sang-Bae, primary, Eun, Young Gyu, primary, Lee, Dong Jin, primary, Conner, Elizabeth A., primary, Factor, Valentina M., primary, Moore, David D., primary, Johnson, Randy L., primary, Thorgeirsson, Snorri S., primary, and Lee, Ju-Seog, primary

Published
2023
Full Text
View/download PDF

44. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

45. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

46. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

48. Prognostic Significance of the BIRC2-BIRC3 Gene Signature in Head and Neck Squamous Cell Carcinoma

Author

LEE, MIN KYEONG, NOH, JOO KYUNG, WOO, SEON RANG, KONG, MOONKYOO, LEE, YOUNG CHAN, LEE, JUNG WOO, KO, SEONG-GYU, and EUN, YOUNG-GYU

Subjects
Cancer Research, Carcinogenesis, Squamous Cell Carcinoma of Head and Neck, Ubiquitin-Protein Ligases, Prognosis, Biochemistry, Baculoviral IAP Repeat-Containing 3 Protein, Inhibitor of Apoptosis Proteins, Gene Expression Regulation, Neoplastic, Head and Neck Neoplasms, Biomarkers, Tumor, Genetics, Humans, Molecular Biology, Research Article, Signal Transduction
Abstract

Background/Aim: Head and neck squamous cell carcinoma (HNSCC) has poor prognosis, with survival rates that have not significantly improved over the past several decades. Therefore, prediction of HNSCC prognosis is of clinical importance. Baculoviral IAP Repeat containing 2 (BIRC2) and Baculoviral IAP Repeat containing 3 (BIRC3) are involved in oncogenic activity by modulating cell proliferation, apoptosis and invasion in HNSCC. This study aimed to develop and validate a predictive gene signature for BIRC2 and BIRC3. Materials and Methods: The genomic copy number and gene expression for BIRC2 and BIRC3 were systematically explored in patients with HNSCC to investigate the clinical relevance of BIRC2 and BIRC3 activation. A prognostic signature was developed based on correlations associated with BIRC2 and BIRC3 mRNA expression and copy number alterations. Hierarchical clustering was used to classify the clusters (Clusters 1 and 2). Moreover, independent validation of the BIRC2-BIRC3 gene signature was performed using the Leipzig, MDACC, FHCRC, and KHU datasets. To explore the biological functions of the BIRC2-BIRC3 gene signature, string analysis and pathway annotation were also performed. Results: BIRC2-BIRC3 gene signature-derived cluster 2 patients exhibited significantly poor survival. This signature also predicted survival in three independent cohorts. Interestingly, the BIRC2-BIRC3 gene signature additionally permitted the identification of survival in advanced tumor stages with excellent accuracy in all three cohorts. Multivariate Cox regression analysis identified that the BIRC2-BIRC3 signature was an independent predictor associated with the survival of patients with HNSCC. Moreover, Inhibition of BIRC2 modulated the NF-ĸB signaling pathway via upregulation of CBR1 expression. Conclusion: The BIRC2-BIRC3 gene signature was found to be associated with the prognosis of HNSCC. Thus, BIRC2 and BIRC3 could be potential targets for improving HNSCC prognosis.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results